Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor-1 and receptor-2 agonists for cancer therapy

Modulation of death receptors by cancer therapeutic agents

(2010) Heath A. Elrod et al.   CANCER BIOLOGY & THERAPY

Mapatumumab, a Fully Human Agonistic Monoclonal Antibody That Targets TRAIL-R1, in Combination with Gemcitabine and Cisplatin: a Phase I Study

(2009) C. H. Mom et al.   CLINICAL CANCER RESEARCH

Targeting apoptosis: preclinical and early clinical experience with mapatumumab, an agonist monoclonal antibody targeting TRAIL-R1

(2009) Patricia Moretto et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Following TRAIL’s path in the immune system

(2009) Christina Falschlehner et al.   IMMUNOLOGY

Mapatumumab, an Antibody Targeting TRAIL-R1, in Combination With Paclitaxel and Carboplatin in Patients With Advanced Solid Malignancies: Results of a Phase I and Pharmacokinetic Study

(2009) Stephen Leong et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Trial of AEG35156 Administered as a 7-Day and 3-Day Continuous Intravenous Infusion in Patients With Advanced Refractory Cancer

(2009) Emma Dean et al.   JOURNAL OF CLINICAL ONCOLOGY

Mapatumumab and lexatumumab induce apoptosis in TRAIL-R1 and TRAIL-R2 antibody-resistant NSCLC cell lines when treated in combination with bortezomib

(2009) T. A. Luster et al.   MOLECULAR CANCER THERAPEUTICS

A novel humanized anti-human death receptor 5 antibody CS-1008 induces apoptosis in tumor cells without toxicity in hepatocytes

(2008) A. Yada et al.   ANNALS OF ONCOLOGY

Death receptor-4 (DR4) expression is regulated by transcription factor NF-κB in response to etoposide treatment

(2008) Francisco José Mendoza et al.   APOPTOSIS

Mcl-1: A Gateway to TRAIL Sensitization

(2008) S.-H. Kim et al.   CANCER RESEARCH

Early Therapy Evaluation of Combined Anti-Death Receptor 5 Antibody and Gemcitabine in Orthotopic Pancreatic Tumor Xenografts by Diffusion-Weighted Magnetic Resonance Imaging

(2008) H. Kim et al.   CANCER RESEARCH

ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor

(2008) C. Tse et al.   CANCER RESEARCH

Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5

(2008) C Adams et al.   CELL DEATH AND DIFFERENTIATION

A Phase 1 Study of Mapatumumab (Fully Human Monoclonal Antibody to TRAIL-R1) in Patients with Advanced Solid Malignancies

(2008) S. J. Hotte et al.   CLINICAL CANCER RESEARCH

Cooperation of the Agonistic DR5 Antibody Apomab with Chemotherapy to Inhibit Orthotopic Lung Tumor Growth and Improve Survival

(2008) H. Jin et al.   CLINICAL CANCER RESEARCH

Treatment of Human Colon Cancer Xenografts with TRA-8 Anti-death Receptor 5 Antibody Alone or in Combination with CPT-11

(2008) P. G. Oliver et al.   CLINICAL CANCER RESEARCH

TRAIL receptor-targeted therapeutics: Resistance mechanisms and strategies to avoid them

(2008) A THORBURN et al.   DRUG RESISTANCE UPDATES

DR4-selective Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) Variants Obtained by Structure-based Design

(2008) Vicente Tur et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

To kill a tumor cell: the potential of proapoptotic receptor agonists

(2008) Avi Ashkenazi et al.   JOURNAL OF CLINICAL INVESTIGATION

Ligand-Based Targeting of Apoptosis in Cancer: The Potential of Recombinant Human Apoptosis Ligand 2/Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand (rhApo2L/TRAIL)

(2008) Avi Ashkenazi et al.   JOURNAL OF CLINICAL ONCOLOGY

Evaluation of Tumor Response, Disease Control, Progression-Free Survival, and Time to Progression As Potential Surrogate End Points in Metastatic Breast Cancer

(2008) Tomasz Burzykowski et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I and Pharmacokinetic Study of YM155, a Small-Molecule Inhibitor of Survivin

(2008) Anthony W. Tolcher et al.   JOURNAL OF CLINICAL ONCOLOGY

Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   JNCI-Journal of the National Cancer Institute

Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer

(2008) F. Anthony Greco et al.   LUNG CANCER

Proteasome inhibitor PS-341 (VELCADE) induces stabilization of the TRAIL receptor DR5 mRNA through the 3'-untranslated region

(2008) K. Kandasamy et al.   MOLECULAR CANCER THERAPEUTICS

Directing cancer cells to self-destruct with pro-apoptotic receptor agonists

(2008) Avi Ashkenazi   NATURE REVIEWS DRUG DISCOVERY

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE

FLIP and the death effector domain family

(2008) J W Yu et al.   ONCOGENE

Selection of Response Criteria for Clinical Trials of Sarcoma Treatment

(2008) S. M. Schuetze et al.   ONCOLOGIST

Endpoints for Assessing Drug Activity in Clinical Trials

(2008) R. Pazdur   ONCOLOGIST

Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist

(2008) A. J. Frew et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

TRAIL and osteoprotegerin: a role in endothelial physiopathology?

(2007) Federica Corallini   Frontiers in Bioscience-Landmark